Fritextsökning
Artiklar per år
Innehållstyper
-
Genmodifierad get ger medicin
Ett nytt läkemedel mot blodpropp har godkänts för försäljning i USA. Preparatet innehåller proteinet antitrombin som produceras i getter som fått en bit mänskligt DNA insatt i sina mjölkörtelceller.
-
IVF ökar inte risk för cancer
En ny dansk studie visar att fertilitetsbehandling inte ökar risken för äggstockscancer. Över femtiotusen kvinnor deltog i studien som är den största hittills av sitt slag.
-
Liten docka kan göra stor nytta
Japanska forskare har tillverkat en levande dockmodell av levercancerceller och collagen. Dockan kan bli ett nytt redskap för att testa nya läkemedel i en miljö som liknar den inne i människokroppen.
-
Helge Sander: "Fler kvinnor behövs"
- Det är något fel när det ena könet i stort sett väljer bort en karriär som forskare, säger Danmarks forskningsminister. Idag håller han rundabordssamtal för att diskutera varför kvinnliga forskare missgynnas. Han välkomnar alla lösningar, utom en.
-
Nytt läkemedel mot Crohns sjukdom
Zealand Pharma tar en ny behandling till klinisk prövning
-
Oncolog får viktig order
Fyra bordstoppar för radioterapi ska levereras i vår till ett stort svenskt universitetssjukhus.
-
KI-forskare får femårig forskningsprofessur
Torsten och Ragnar Söderbergs stiftelser ger Christer Betsholtz möjlighet att i fem år heltidsforska om tillväxtfaktorers roll i cancer
-
Roche sänker budet på Genentech
I juli ifjol var budet 89 dollar per aktie. Då sa Genentechs styrelse nej tack. Nu meddelar läkemedelsjätten att man sänker budet och vänder sig direkt till småägarna.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Athera signs production partnership
The companys novel cardiovascular product will be manufactured in Germany.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Teams up with leading dermatologist
Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
-
New study of toxins and heart disease
Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study will try to evaluate this, and one thousand people are to be included.
-
Less scars with new product
A new Swedish product for post surgical scar formation enters clinical development.
-
EUR 2 million for peanut allergies
ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.
-
Almost 150 will leave Coloplast
The Danish medtech company Coloplast negotiates headcount reductions, with a total number of almost 150 employees.
-
Biotage is regrouping
The Swedish company Biotage takes yet another step in streamlining efforts, by outsourcing all instrument production to contract manufacturers.
-
Researchers goes to the bottom of the brain
Swedish researchers have recently got new and deeper knowledge about the smallest part of the brain, the granule cells.
-
Vitamin D is mental health aid
Vitamin D can help stave off the mental decline that can affect people in old age, a study suggests.
-
EU says yes to Roche drug
EU approves a first in class therapy for treatment of patients with moderate to severe form of rheumatoid arthritis.
-
Lytix calls in cash
Norwegian company Lytix Biopharma closes a USD 1.4 million funding round to finance new antimicrobial and oncology lead compounds.
BREAKING